Skip to main content

Sequenom Stock Surges 13 Percent on Positive Study Results

NEW YORK, March 27 (GenomeWeb News) - Shares in Sequenom were up 13.29 percent, or $.09, at $.75 in mid-afternoon trading today after the company said two proof-of-concept molecular diagnostic studies using its MassArray system have garnered positive results.

According to Sequenom, the studies, which were performed at different CLIA-certified laboratories, tested for cystic fibrosis and Factor V Leiden and "yielded absolute equivalence of analytical results generated by the MassArray Compact system when compared with well established systems in current use."

 

The studies were conducted and evaluated by Siemens Medical Solutions of Siemens; Specialty Laboratories; and Bioscientia Institut fur Medizinische Diagnostik, and were part of the molecular diagnostics benchmarking study that was initiated in late 2004 by Siemens and Sequenom.

 

As part of the proof-of-concept research, Specialty Laboratories and Bioscientia tested approximately 1,500 DNA samples for Factor V Leiden and Specialty tested more than 1,000 DNA samples for CFTR, according to Sequenom.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.